A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA): a phase II study of the Fondazione Italiana Linfomi (FIL).

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506206-38-00

Acronym

FIL_RICCO

Enrollment

Registered

2025-02-11

Start date

2025-04-09

Completion date

Unknown

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B-cells non-Hodgkin Lymphoma

Brief summary

Progression free survival (PFS)

Detailed description

Overall response rate (partial response, PR + complete response, CR) after the 6th cycle, Overall survival (OS), Rate of treatment discontinuation due to AE or treatment intolerance, Change in QoL assessment from baseline at 6 months and 12 months by EORTC QLQ C-30 and FACT-Lym questionnaires

Interventions

DRUGGolcadomide

DRUGRITUXIMAB

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free survival (PFS)	—

Secondary

Measure	Time frame
Overall response rate (partial response, PR + complete response, CR) after the 6th cycle, Overall survival (OS), Rate of treatment discontinuation due to AE or treatment intolerance, Change in QoL assessment from baseline at 6 months and 12 months by EORTC QLQ C-30 and FACT-Lym questionnaires	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026